clinical trial · NCT07515820
SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study
Meng Qiu·phase2·not yet recruiting·n = 12
Colorectal CancerSHR-3821 and fruquintinib
brief summary
To evaluate the safety and efficacy of SHR-3821 combined with fruquintinib in the advanced colorectal cancer after failure of standard therapy
started
Apr 27, 2026
primary completion
Jul 28, 2027
completion
Apr 28, 2028
last updated
Apr 7, 2026
detailed description
This is a single-center, open-label, exploratory phase II clinical trial designed to investigate the efficacy and safety of SHR-3821 in combination with fruquintinib for the treatment of metastatic colorectal cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol